Altogen Labs HL-60 Xenograft Service Leukemia

Описание: Altogen Labs http://altogenlabs.com provides xenograft services http://altogenlabs.com/xenograft-mode.... The tumorigenic HL-60 cell line was derived from the peripheral blood tissue of a 36-year-old female patient with acute promyelocytic leukemia (APL). While being primarily effective in leukemia research, it is suitable for biomedical applications as a transfection host.
The HL-60 human leukemia cell line is used to create the CDX (Cell Line Derived Xenograft) HL-60 xenograft mouse model, a commonly used model to assess the effectiveness of drugs against leukemia and enabling screening studies of acute myeloid leukemia (AML) therapeutics. The HL-60 xenograft model is useful for biomedical research related to leukemia.
Xenografting is the transplantation of tissue from one species into another.
Xenografting has been established as benchmark studies in pre-clinical cancer research.
Typically, immunodeficient mice serve as hosts for a wide variety of human tumors, effectively serving as models for human subjects.
Xenografting is a complete and accurate study of tumor growth and the activity of drug administration.


-HL-60 Xenograft Model
Sample Cell Lines Available

-HL-60 Xenograft Model
Advantages of Xenografting
Develop new therapeutic agents quickly, efficiently and cost-effectively
Evaluate the efficacy and toxicity of potential therapeutic agents
Evaluate target compound activity using in vivo system (human cells)
Predict cytotoxicity of cancer drugs

-HL-60 Xenograft Model
Basic Xenograft Study
Xenograft studies can be designed to:
Identify lead compounds
Optimize dose schedules
Identify combination strategies

-HL-60 Xenograft Model
Routes of drug administration:
Intratumoral
Intramuscular
Oral gavage
Intravenous
Intratracheal
Subcutaneous
Intraperitoneal
Continuous infusion
Intranasal
Using cutting-edge micro-injection techniques

-HL-60 Xenograft Model
Following options are available for the HL-60 xenograft model:
HL-60 Tumor Growth Delay (TGD; latency)
HL-60 Tumor Growth Inhibition (TGI)
Dosing frequency and duration of dose administration
HL-60 tumor immunohistochemistry
Alternative cell engraftment sites (orthotopic transplantation, tail vein injection and left ventricular injection for metastasis studies, injection into the mammary fat pad, intraperitoneal injection)
Blood chemistry analysis
Toxicity and survival (optional: performing a broad health observation program)
Gross necropsies and histopathology
Positive control group employing cyclophosphamide, at a dosage of 50 mg/kg administered by intramuscular injection to the control group daily for the study duration
Lipid distribution and metabolic assays
Imaging studies: Fluorescence-based whole body imaging, MRI

-HL-60 Xenograft Model
Altogen Labs’ team of scientists carries extensive experience in Xenograft model research.
Altogen Labs is compliant as a Good Laboratory Practices (GLP) environment, which is required by the FDA for pre-clinical research.
Our Altogen Labs’ Xenograft services are extensive, rigorous, and flexible.
Contact us to discuss Xenograft model details, timeline estimates, and price quotes!

Connect to Altogen Labs:
LinkedIn -   / altogen-labs  
Twitter - https://twitter.com/altogen?lang=en
Facebook -   / altogen.cro